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ABSTRACT: The natural product
austocystin D was identiﬁed as a
potent cytotoxic agent with in vivo
antitumoractivityandselectivityfor
cells expressing the multidrug resis-
tance transporter MDR1. We
sought to elucidate the mechanism
of austocystin D’s selective cytotoxic activity. Here we show that the selective cytotoxic action of austocystin D arises from its
selective activation by cytochrome P450 (CYP) enzymes in speciﬁc cancer cell lines, leading to induction of DNA damage in cells
and in vitro. The potency and selectivity of austocystin D is lost upon inhibition of CYP activation and does not require MDR1
expression or activity. Furthermore, the pattern of cytotoxicity of austocystin D was distinct from doxorubicin and etoposide and
unlikeaﬂatoxinB1,acompoundthatresemblesaustocystinDandisalsoactivatedbyCYPenzymestoinduceDNAdamage.Theses
results suggest that austocystin D may be of clinical beneﬁt for targeting or overcoming chemoresistance.
C
hemoresistance is a serious challenge to successful cancer
treatment. A common mechanism of acquired resistance to
chemotherapeutics is the overexpression of ATP-binding cas-
sette transport proteins (ABC transporters) including MDR1,
the multidrug resistance-associated protein 1 (MRP1), and the
breast cancer resistance protein (BCRP).
1 These transporters
mediate the ATP-dependent eﬄux of a variety of chemicals.
MDR1 serves the physiological role of protecting the body from
toxic chemicals.
2 Cancer cells, however, use it to pump out
chemotherapeutic agents, thereby reducing treatment eﬃcacy.
To circumvent this resistance to chemotherapeutic agents, eﬀort
has focused on the discovery and development of small mole-
cules that are selectively toxic to cancer cells that overexpress
ABC transporters.
The natural product austocystin D (1, Figure 1) was isolated
from Aspergillus isolate UGM218 as a potent and selectively
cytotoxic agent in a 26-cell-line panel.
3 On the basis of its selec-
tive cytotoxicity, austocystin D generated interest as a promising
lead anticancer compound. Austocystin D is unusual in that it is
cytotoxic to cell lines that overexpress MDR1, also known as
P-glycoprotein. In fact, austocystin D was observed to be 20-fold
more potent in cell lines in which MDR1 was overexpressed by
drugselectionortransfection.
3Thecompoundwassubsequently
foundtobeactiveinvivo;itinhibitedthegrowthofhumancolon
carcinoma cell line LS174T subcutaneously implanted in nude
mice.
3Whileseveralaustocystinshavebeenidentiﬁedasbacterial
mutagens,
4 it was unclear whether DNA damage accounted for
the antitumor and unique cell-line selective activity of
austocystin D.
Therehavebeenanumberofattemptstoidentifythetargetof
austocystin D, including the use of aﬃnity chromatography and
geneexpressionproﬁlinginyeast.Theseattemptshavenotledto
the discovery of the cellular target for and the mechanism of
actionofaustocystinD’sselectiveantiproliferativeactivity.
3Here
we describe the elucidation of the mechanism of action of
austocystin D. The selective cytotoxicity of austocystin D did
not fully correlate with ABC transporter expression, although
austocystin D did act as an MDR1 substrate. Instead, austocystin
D cytotoxicity correlated with activation of a DNA damage
response pathway and cytochrome P450 (CYP) activity. Both
ketoconazole, an inhibitor of CYP 3A4 at low doses and other
CYP enzymes at higher doses,
5 and chemical modiﬁcation to
block the likely site of CYP activation diminished austocystin D
cytotoxicity. Finally, we observed that austocystin D directly
damaged DNA in vitro, but only in the presence of mammalian
liver microsomes. Therefore, austocystin D is activated by CYP
enzymes to directly damage DNA, and the selective antiproli-
ferative action is due to selective CYP enzyme activity. These
studies provide an explanation for the selective antiprolifera-
tive action of austocystin D and point to the possible utility of
Received: July 6, 2010568 dx.doi.org/10.1021/np100429s |J. Nat. Prod. 2011, 74, 567–573
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targeting diﬀerences in CYP enzyme expression to overcome
chemoresistance.
’RESULTS AND DISCUSSION
AustocystinDIsaPotentandHighlySelectivelyCytotoxic
Natural Product with Activity Unlike That of Doxorubicin,
Etoposide, and Aflatoxin B1. Austocystin D was tested for
cytotoxicity after 72 h treatment in a panel of cell lines. As
indicatedinTable1,austocystinDdisplayedpotentcytotoxicity,
with GI50 values below 10 nM for three cell lines, and marked
selectivity, with greater than 10000-fold selectivity between the
most sensitive cell line (MCF7) and the least sensitive cell line
(MES-SA). The selectivity of austocystin D was not easily
explained by tissue origin, as demonstrated by a comparison of
MCF7 and MCF10A breast cell lines, where a selectivity of
greater than 1000-fold was observed for MCF7 cells (Figure 2a).
Furthermore, the selectivity and activity was unlike that of
chemotherapeutic agents such as doxorubicin and etoposide,
both ∼50-fold more toxic to MCF10A cells, or the structurally
related aflatoxin B1, which did not display selectivity or potency,
with GI50 values in each cell line above 5 μM (Figure 2). The
differential selectivity to that of doxorubicin and etoposide indi-
cates that austocystin D may have the potential to overcome
resistancetotheseagents,andthedifferentialpotencytoaflatoxinB1
indicates that these structurally related natural products (Figure 1)
may not share a related mechanism of action or cellular activity.
Austocystin D Directly Interacts with MDR1, But This
Interaction Is Not Required for Its Cytotoxic Activity. Since
austocystin D was previously shown to display selective cyto-
toxicity to cells overexpressing the ABC transporter MDR1, we
investigated the possibility that austocystin D interacts directly
with this transporter. MDR1 drug efflux activity is accompanied
by ATP hydrolysis and therefore can be monitored in vitro by
measuring the production of inorganic phosphate from mem-
branes containing MDR1.
6 Similar to known MDR1 substrates,
verapamil and vinblastine,
1 austocystin D stimulated ATPase
activity in this assay, suggesting that it is also likely to be an
MDR1 substrate (Figure 3a). Furthermore, cyclosporin A, a
known inhibitor of the substrate-stimulated MDR1 ATPase
activity,
7 fully inhibited austocystin D-stimulated ATPase activity.
To determine whether austocystin D also modulated drug
eﬄux activity in cells, we measured the abundance of the ﬂuo-
rescent dye calcein in live cells.
8 In this assay, the nonﬂuorescent
calcein acetoxymethyl ester (calcein-AM) is added to cells and is
hydrolyzed to calcein by cellular esterases. Calcein-AM is an
MDR1 and MRP1 family substrate and thus is actively eﬄuxed
from cells expressing those transport proteins, resulting in low
levels of retained ﬂuorescence.
9 MDR1 and MRP1 family sub-
strates or inhibitors prevent calcein-AM eﬄux, leading to high
levels of retained ﬂuorescence. Similar to MDR1 substrate
verapamil and inhibitor cyclosporin A, austocystin D inhibited
eﬄux of calcein-AM, indicating that it can also modulate drug
eﬄux activity in cells (Figure 3b).
AlthoughaustocystinDmodulatedABCtransporteractivityin
vitro and in cells, this activity does not account for the cytotoxi-
city of austocystin D. Verapamil and austocystin D both act as
MDR1 substrates with similar cellular activity, yet verapamil is
morethan1000-foldlesscytotoxicthanaustocystinD(Figure3c,
d). Furthermore, we evaluated a panel of cell lines for ABC
transporter activity in relation to austocystin D sensitivity. We
measured calcein-AM eﬄux as an indication of the presence of
functional MDR1 or MRP1 family members and Hoechst 33342
Figure1. StructuresofaustocystinD(1),aﬂatoxinB1(2),anddihydro-
austocystin D (3).
Table 1. Growth Inhibition by Austocystin D
tissue type cell line GI50 nM (n)
Normal
umbilical vein endothelial HUVEC 4249 (2)
breast MCF-10A 3513 (3)
Cancer
non-small-cell lung A549 >5000 (5)
cervix HeLa >5000 (5)
leukemia SR 16 (2)
brain glioblastoma U87 4946 (3)
breast MCF-7 <1 (3)
breast MDA-MB-231 549 (3)
prostate PC-3 3 (2)
colon SW620 27 (2)
colon HCT-15 42 (2)
uterine MES-SA >10000 (2)
uterine MX2 3358 (2)
Figure 2. Austocystin D potency and selective cytotoxicity is distinct
from doxorubicin, etoposide, and aﬂatoxin B1. Dose-dependent growth
inhibition of tissue-matched transformed, MCF7, and nontransformed,
MCF10A, cells after 72 h treatment with (a) austocystin D, (b)
doxorubicin, (c) etoposide, and (d) aﬂatoxin B1. Vertical bars represent
SEM, representative experiments shown.569 dx.doi.org/10.1021/np100429s |J. Nat. Prod. 2011, 74, 567–573
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eﬄux as an indication of the presence of functional BCRP family
members.
9,10AsindicatedinTable2,SW620cellslackedactivity
for known ABC transporters yet were sensitive to austocystin D.
Taken together, the lack of correlation between verapamil and
austocystin D cytotoxicity and ABC transporter activity provides
strong evidence that the cytotoxicity of austocystin D is not due
to its interaction with ABC transporters.
Austocystin D Is a Cytochrome P450-Activated DNA
Damage Agent. Because of its structural similarity to aflatoxin
B1, a CYP-activated mutagen,
11 we investigated whether the
selective cytotoxic activity of austocystin D was due to CYP-
activated DNA damage. Austocystin D and aflatoxin B1 share a
vinylethermoiety,criticalinaflatoxinB1foritsbiologicalactivity
(Figure 1). This moiety in aflatoxin B1 undergoes epoxidation
catalyzedbyCYPenzymes,andtheresultingepoxideformsDNA
adducts.
11 To detect cellular DNA damage, we established an in-
cell Western assay measuring the phosphorylation levels of
histone H2AX. Histone H2AX is phosphorylated by the kinase
ATM at serine 139 in response to DNA double strand breaks.
This signal occurs in response to DNA-damaging agents such as
bleomycin and camptothecin
12,13 and is a sensitive readout of
DNA damage response pathways.
14 In this assay, we observed
thatknownDNAdamageagentscamptothecin,doxorubicin,and
bleomycin induced dose-dependent phosphorylation of histone
H2AX after 4 h of drug treatment (Figure 4a, Figure S1a,b). We
subsequently determined that austocystin D induced the phos-
phorylation of histone H2AX in cell lines for which it was cyto-
toxic (Figure 4a,b). Thus, austocystin D caused a cell-line selective
inductionoftheDNAdamageresponsethatmatcheditscell-line
selective cytotoxicity.
To investigate the likelihood that austocystin D required CYP
activationtoinducetheDNAdamageresponseandbecytotoxic,
we treated cells with both ketoconazole, a cell-permeable inhibitor
of CYP 3A4 activity,
5 and austocystin D. Ketoconazole fully
prevented austocystin D cytotoxicity and induction of the DNA
damageresponse,demonstratingthatCYPactivityisrequiredfor
austocystinD’santiproliferativeactivity(Figure5a,b).Thiseﬀect
was speciﬁc to austocystin D and did not result from general
inhibition of the DNA damage response (Figure 5c).
CYP activation of aﬂatoxin B1 occurs via epoxide formation at
the vinyl ether. The epoxide forms a direct covalent interaction
with guanine nucleotides, causing DNA damage.
11 We sought to
Figure 3. Austocystin D modulates MDR1 activity in vitro and in cells. (a) Eﬀect of austocystin D (ausD) and MDR1 substrates verapamil (ver) and
vinblastine (vin) on the ATP hydrolysis by membranes containing MDR1 in the presence (dashed lines) or absence (solid lines) of 1 μM MDR1
inhibitorcyclosporinA(csA).AustocystinD,verapamil,andvinblastineeachactivatedMDR1ATPhydrolysisthatwasinhibitablebycyclosporinA.(b)
Eﬀectof10μMaustocystinD,40μMverapamil,and10μMcyclosporinAontheretentionofcalceininHCT-15cells.AustocystinDbehavedsimilarly
to verapamil and cyclosporin A to inhibit calcein-AM eﬄux and thereby increase intracellular calcein ﬂuorescence relative to vehicle (DMSO)-treated
cells. (c, d)Eﬀectofaustocystin Dand verapamilon(c)calcein-AM eﬄux and(d) growth inHCT-15 cells. Vertical barsrepresent SEM, representative
experiment shown.
Table2. Austocystin DCytotoxicityDoesNotCorrelatewith
Drug Eﬄux Activity
a
cell line GI50 (nM) MDR1/MRP activity BCRP activity
MCF7 <1 - þ (subset of cells
b)
MCF10A 3513 --
HCT-15 42 þ not determined
SW620 27 --
MES.SA >10000 - not determined
MES.SA/MX2 3358 þ not determined
aAt least two independent experiments were performed for each
data point.
b<50% of MCF7 cells displayed BCRP activity.570 dx.doi.org/10.1021/np100429s |J. Nat. Prod. 2011, 74, 567–573
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probe the involvement of an austocystin D epoxide intermediate
by hydrogenation of the vinyl ether, since the aﬂatoxin B1
epoxide intermediate is known to be short-lived under physio-
logicalconditions,
15andwethereforeexpectedtheaustocystinD
epoxide to also be short-lived. We reduced the vinyl ether of
austocystinD,yieldingdihydro-austocystinD
16(3,Figure1)and
observed that dihydro-austocystin D displayed only very weak
cytotoxicity and induction of the DNA damage response, further
supporting the importance of metabolic activation for the
mechanism of action of austocystin D (Figure 5d,e).
To support the cellular data indicating that austocystin D
inducedDNAdamagefollowingCYPactivation,weappliedanin
vitro reconstituted DNA damage assay.
17,18 In this assay,
supercoiled plasmid DNA is incubated with compound in the
presence or absence of human liver microsomes, a rich source of
CYP enzymes, and an NADPH regenerating system to generate
in situ the NADPH that is required for the CYP activity.
Alkylation of DNA leads to single strand breaks, which relax
thesupercoiledDNA.TheresultingnickedDNAcanbedetected
byagarosegelelectrophoresis.Inthisassay,austocystinDcaused
direct DNA damage at 100 nM, consistent with the compound’s
GI50 in cells (Figure 6 and Table 1). This in vitro DNA damage
activity required CYP activity, as increased nicked DNA was
observed only in the presence of both liver microsomes and the
NADPH regenerating system required for activity of CYP
enzymes in vitro.
Figure 4. Austocystin D displayscell-line-selective DNA damage that correlates with cytotoxicity. (a) In-cellWestern showingthe eﬀect ofaustocystin
D, doxorubicin, bleomycin, and DMSO (vehicle) on levels of phosphorylated histone H2AX (pH2AX) after 4 h treatment of HCT-15 cells. (b) In-cell
Western datashowingtheeﬀectofaustocystinDonpH2AXinSW620, HCT-15,andHeLacellsfollowing1hoftreatment.72hGI50valuesareshown
for comparison in parentheses. Vertical bars represent SEM.
Figure5. InhibitionofCYPorhydrogenationofaustocystinDabrogatesaustocystinDDNAdamageandcytotoxicity.(a)InhibitoryeﬀectoftheCYP
inhibitorketoconazoleonHCT-15cellgrowthinhibitionof0.5μM(lightblue),1μM(blue),and2μM(darkblue)austocystinD.(b)Inhibitoryeﬀect
of 10 μM ketoconazole on austocystin D-induced phosphorylation of histone H2AX in HCT-15 cells following 1 h ketoconazole pretreatment and 4 h
austocystin D treatment. (c) Speciﬁc inhibition of 10 μM ketoconazole (Ket) on 10 μM austocystin D-induced phosphorylation of histone H2AX in
SW620 cellsin comparison to20 μM camptothecin. (d, e)Comparison ofaustocystinDanddihydro-austocystin Dfor(d)growth inhibitionafter 72 h
treatment of MCF7 cells and (e) induction of phosphorylation of histone H2AX after 4 h in MCF7 cells. Vertical bars represent SEM.571 dx.doi.org/10.1021/np100429s |J. Nat. Prod. 2011, 74, 567–573
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’DISCUSSION
Austocystin D was originally discovered more than 30 years
ago in an eﬀort to identify and characterize secondary metabo-
lites in maize meal cultures of Aspergillus ustus (Bainier) Thom.
and Church.
16 More recently, it was reported to act as a
selectively cytotoxic agent to certain cancer cell lines with an
apparent selectivity toward cells expressing MDR1.
3 We sought
toelucidatethemechanismofactionofaustocystinDtouncover
a potentially useful approach to selectively target chemoresistant
cancer cells that act by expression of ABC transporters. Our
approach involved the investigation of two possible leads: that
ABC transporter activity might be required for austocystin D
antiproliferative activity and that austocystin D might act by a
mechanism similar to aﬂatoxin B1, a well-characterized structu-
rally related compound that is activated by CYP enzymes to
induce DNA damage.
We began by conﬁrming the cell-line selectivity of austocystin
D and found it to be remarkably potent and selective, displaying
over 1000-fold selectivity between sensitive and resistant cell
lines.Incomparisontothechemotherapeuticagentsdoxorubicin
and etoposide, austocystin D displayed a reverse sensitivity pattern
between the breast cancer cell line MCF7 and the proliferative
nontransformed breast cell line MCF10A with the advantage of
being more selective for the cancer cell line. Austocystin D was
also only weakly active against the normal human umbilical vein
endothelial cell line (HUVEC), suggesting the possibility of selec-
tivelytargetingcancercells,particularlyinthesettingofresistanceto
standard chemotherapy. Further characterization of a subset of
cell lines revealed that ABC transporter activity did not correlate
withaustocystinDantiproliferativeactivity.Forexample,SW620
cells were highly sensitive to austocystin D with a GI50 of 27 nM
but did not display ABC transporter activity.
ToinvestigatethepossibilitythataustocystinDinducedDNA
damage in cells, we measured the induction of phosphorylation
of histone H2AX, which occurs in response to DNA damage.
Austocystin D induced histone H2AX phosphorylation, and this
activity fully correlated with its cellular cytotoxicity. The histone
H2AX phosphorylation and antiproliferative activity could be
fully inhibited by treatment with ketoconazole, a CYP inhibitor
with highest potency toward CYP 3A4, or reduction of austo-
cystin D to dihydro-austocystin D, a form that was not expected
toundergoCYP-catalyzedepoxidationlikeaﬂatoxinB1.
11There-
fore,amechanismemergedinwhichaustocystinDisactivatedby
CYP enzymes to induce DNA damage leading to cell death.
Further support for this mechanism of action came from in vitro
experiments in which we directly observed DNA damage in the
presence of liver microsomes expected to contain CYP enzymes.
While austocystin D and aﬂatoxin B1 share a similar mode of
action in vitro and in the Ames test,
4 namely, CYP-activated
DNA damage, the compounds diﬀer dramatically in both po-
tency and cell-line selectivity. In the comparison between MCF7
and MCF10A, aﬂatoxin B1 displayed little selectivity and poor
potency, while austocystin D was highly selective and potent,
being 1000-fold more active against MCF7 cells. Although both
compounds contain a vinyl ether moiety, the remainder of the
structures may encode CYP enzyme speciﬁcity or sensitivity, or
diﬀerences in DNA recognition. Alternatively, the reactivity of
the vinyl ether or epoxide may vary between the compounds,
leading to diﬀerences in rate of epoxide formation or covalent
interaction with cellular DNA. One possibility for the diﬀerence
in activity between austocystin D and aﬂatoxin B1 is the absence
of a tertiary alcohol in aﬂatoxin B1 adjacent to the site of
epoxidation. This hydroxyl is present in aﬂatoxin M1, a metabo-
liteofaﬂatoxinB1.
19Nealetal.directlycomparedthecytotoxicity
of aﬂatoxins B1 and M1 and reported diﬀerences; the human B
lymphoblastoid cell line MCL-5 that stably expresses CYPs 1A2,
2A6, 3A4, and 2E1 and microsomal epoxide hydrolase was
sensitive only to aﬂatoxin B1, while the untransfected line, cHol,
was sensitive only to aﬂatoxin M1.
20 A comparison of the
biological activity of austocystin D to aﬂatoxin M1 will help
reveal the importance of the tertiary alcohol to diﬀerences
between austocystin D and aﬂatoxins. In addition, an investiga-
tion into CYP selectivity and hepatoxicity will help reveal
distinctions between austocystin D and aﬂatoxins and the
potential clinical utility of austocystin D.
Despite its initial discovery as an MDRþ cell selective agent,
we have determined here that the unusual selectivity of austo-
cystin D is mediated by CYP activation, rather than by a direct
Figure 6. Austocystin D mediates direct DNA damage in vitro in the presence of liver microsomes. (a) DNA agarose gel showing the eﬀect of 1 μM
austocystin D on converting supercoiled plasmid DNA to nicked DNA after treatment with diﬀerent additives. (b) DNA agarose gel showing the
potency of austocystin D-induced DNA nicking.572 dx.doi.org/10.1021/np100429s |J. Nat. Prod. 2011, 74, 567–573
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interaction with ABC transporters. This unanticipated ﬁnding is
likely explained by coordinate expression of CYPs and ABC
transporters by the pregnane xenobiotic receptor (PXR) or the
constitutive androstane receptor (CAR) nuclear hormone re-
ceptors. These receptors induce the expression of a coordinated
cellular detoxiﬁcation program in response to xenobiotic small
molecules, and each is known to upregulate both ABC transpor-
ters and CYP enzymes.
21,22 Thus, our ﬁndings support a model
whereby transcriptional upregulation of ABC transporters by
PXR/CAR can lead to a multiple drug resistance phenotype and
thatthistranscriptionalprogramalsoinducestumoralexpression
of CYP enzymes. This model is also supported by the observa-
tions that PXR agonists lead to multiple drug resistance and that
chemotherapeutics prone to multiple drug resistance induce
PXR-mediated transcription.
22-24
Theseﬁndingssuggest acontext-dependentcytotoxicity strat-
egy for the design of new therapeutics for multiple drug resistant
cancers, where the co-regulation of MDR and CYP enzymes
createsavulnerabilitytoCYP-activatedprodrugsthataredirectly
activated in the tumor tissue. Previous CYP-activated anticancer
agents, such as cyclophosphamide, have relied on metabolic
activation of the drug in the liver.
25,26 Such drugs have limited
cancer cell autonomous eﬀects and require liver activation for
activity. This is typically associated with systemic toxicity as the
activated drug enters circulation.
25 In the present work, we show
that austocystin D has signiﬁcant cancer cell autonomous activity,
suggesting that the molecule or derivatives could be suitably
activated directly within tumors. Due to the coordinate expres-
sion of CYPs and ABC transporters such as MDR1, the natural
product austocystin D or compounds with a similar mechanism
of action have the potential to target multiple drug resistant
tumors, and thus may address a signiﬁcant clinical need.
’EXPERIMENTAL SECTION
GeneralExperimentalProcedures. AustocystinDwasisolated
as previously described,
27 and dihydro-austocystin D was synthesized as
described in the Supporting Information and has previously been
synthesized.
16 All other compounds were obtained from commercial
suppliers.
Cytotoxicity Testing. HUVEC cells were obtained from Lonza,
and other cell lines were obtained from ATCC. All cell lines were
maintained according to manufacturer specifications. Cells were plated
in96-wellplatesatdensitiesrangingfrom2500to10000cells/well24h
prior to the addition of compounds. Compound stocks in 100% DMSO
were 3-fold serially diluted in 100% DMSO in 96-well U-bottom plates
to generate 1000  dose curves. These were subsequently diluted 1:100
in RPMI-1640 medium and then diluted 1:10 into the wells plated with
cells for a final DMSO concentration of 0.1%. The Cell-Titer Blue viability
assay (Promega) was performed at 0 and 72 h of compound treatment.
GI50 values for compounds were determined relative to DMSO control
samplesmeasuredat0h(0%growth)and72h(100%growth).Allcurve
fitting wasperformed usingnonlinear regression withGraphPad Prism5
software.
In Vitro MDR1 ATPase Assay. Drug-stimulated MDR1 ATPase
activity was determined by measuring inorganic phosphate release.
6
Human MDR1 and control membranes (BD Biosciences) were pre-
pared in assay buffer (50 mM Tris-Mes pH 6.8, 1 mM EGTA, 1 mM
dithiothreitol, 25 mM KCl, 2.5 mM sodium azide) with and without
cyclosporin A (50 μM final concentration). Compounds were added to
membranesandincubatedfor10minat37C,andtheATPasereaction
was initiated by the addition of ATP. The final concentrations of
membrane, ATP, and DMSO in the reactions were 200 μg/mL,
4mM,and1%,respectively. Thereactionswerestoppedbytheaddition
of SDS solution containing antifoam A (final concentration of 3%) after
0 and 60 min incubation periods. Two equal volumes of 35 mM
ammonium molybdate in 15 mM zinc acetate:/10% ascorbic acid (1:4)
were subsequently added followed by a 20 min incubation at 37 C and
measurement of absorbance at 800 nm. The released inorganic phos-
phate was determined by comparison to a phosphate standard curve at
800 nm. The MDR1-specific ATPase activity was calculated by compar-
ing ATPaseactivityfromMDR1membranestothatofcontrolmembranes.
MDR1/MRP Activity. MDR1/MRP cellular activity was deter-
mined by measuring calcein-AM efflux.
28 Cells were plated in triplicate
wellsatadensityof5 10
5cellspersix-well2dayspriortotheassay.For
the assay, cells were treated with compounds for 60 min at 37 C
followed by the addition of calcein-AM (0.25 μM). After 30 min at
37 C, the cells were washed twice with PBS, trypsinized, suspended in
cold PBS, and analyzed with a FACS Calibur equipped with a 488 nm
argonlaser(Becton-Dickinson).InFigure3c,themeanfluorescenceof
each histogram was calculated for austocystin D and verapamil at the
indicated doses in duplicate, andthe average oftwo samples was plotted
with GraphPad Prism5, as above. DMSO was set to 100% ABC
transporter activity, and 100 μM verapamil was set as 0% ABC transporter
activity for normalization.
BCRP Activity. BCRP cellular activity was determined by measur-
ing Hoechst 33342 efflux.
10 Cells were trypsinized from semiconfluent
150cm
2plates,resuspendedat10
6cells/mLinmedia(RPMI-1640,10%
FBS), and incubated with 5 μg/mL Hoechst 33342 at 37 C. After 45
min, cells were washed once with cold Hanks balanced saline solution
supplemented with 1 mM HEPES and 2% FCS (HBSSþ) and resus-
pended in media (RPMI-1640, 10% FBS) with 10 μM fumitremorgin C
at 37 C. After 20 min, cells were washed with cold HBSSþ, resus-
pended in cold HBSSþ containing 2 μg/mL propidium iodide (PI) to
exclude nonviable cells, and analyzed with a FACS LSRII (BD Bio-
sciences) equipped with 360 nm UV and 488 nm argon lasers.
In-Cell Western Assay for Phosphorylation of Histone
H2AX. Cells were plated in 96-well black-walled plates at 10000
cells/well 24 h prior to the addition of compounds. Compound stocks
in 100% DMSO were 3-fold serially diluted in 100% DMSO in 96-well
U-bottom plates to generate 1000  dose curves. These were subse-
quentlydiluted1:100inRPMI-1640mediumandthendiluted1:10into
thewellsplatedwithcellsforafinalDMSOconcentration of0.1%.After
4hat37C,cellswerefixedin4%paraformaldehydefor20min,washed
briefly in 0.1% Tween-20, and permeabilized in 0.1% Triton-X 100 in
PBS. After 20 min, cells were incubated in blocking buffer (Licor
Biosciences, Odyssey blocking buffer) for 1 h and incubated overnight
with antiphospho-H2AX antibody (Cell Signaling Technology, phos-
pho-H2A.X Ser139) at 1:400 in blocking buffer. The cells were subse-
quently washed and incubated with goat-anti-rabbit IR800CW (Licor
Biosciences) at 1:800 in blocking buffer and DRAQ5 (Biostatus Limit-
ed)at1:10000.After1h,cellswerewashedwithPBSwith0.1%Tween-
20. Signals were detected with a Licor Odyssey infrared scanner (Licor
Biosciences) at 700 and 800 nm. Each well was normalized within the
well by taking the ratio of 800 nm/700 nm. Ratios of duplicate or
triplicate wells were averaged and normalized to the in-plate controls
0.1% DMSO (0% induction) and 10 μM etoposide (100% induction).
Curvefittingwasperformedasforcytotoxicitytesting.Forketoconazole
experiments,cellswerepretreatedwith10μMketoconazolefor1hprior
to the 4 h treatment with austocystin D or camptothecin.
In Vitro DNA Damage Assay. Supercoiled pLenti6 plasmid
DNA (120 μg/mL) was incubated at 37 C with compound (100 nM,
500 nM, or 1 μM; 1% DMSO final concentration) in the absence or
presenceofhumanlivermicrosomes(0.25mg/mL;CellzDirect)andan
NADPH regenerating system (1.5 mM NADP, 12.5 mM glucose-6-
phosphate, 0.25 U/mL glucose-6-phosphate dehydrogenase, 100 mM
phosphatepH7.5,5mMMgCl2).After4h,thereactionwasstoppedby573 dx.doi.org/10.1021/np100429s |J. Nat. Prod. 2011, 74, 567–573
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addition of an equal volume of phenol/chloroform (1:1) solution. After
vigorous vortexing, the emulsion was separated by centrifugation, and
theDNAwasrecoveredfromtheaqueousphasebyusingagelextraction
kit(Qiagen).ThepurifiedDNAwasthensubjectedtoelectrophoresisin
TAE buffer using a 0.8% agarose gel, and the bands were photographed
using Biorad Gel Doc.
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